| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Bo Ahrén | Q5544506 |
| P2093 | author name string | Filipsson K | |
| Kvist-Reimer M | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 1959-1969 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function | |
| P478 | volume | 50 |
| Q46948267 | Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines |
| Q38260861 | Beta cell connectivity in pancreatic islets: a type 2 diabetes target? |
| Q28594896 | Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology |
| Q27008275 | Cyclic AMP dynamics in the pancreatic β-cell |
| Q42637970 | Effect of pituitary adenylate cyclase-activating polypeptide in islet transplantation |
| Q36513195 | Feeding and metabolism in mice lacking pituitary adenylate cyclase-activating polypeptide |
| Q31157033 | Gut peptides and type 2 diabetes mellitus treatment |
| Q51742003 | HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. |
| Q24562990 | Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM |
| Q35871904 | Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? |
| Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
| Q44044533 | Mouse pituitary adenylate cyclase-activating polypeptide (PACAP): gene, expression and novel splicing |
| Q41665744 | Neuropeptide signaling and hydrocephalus: SCO with the flow |
| Q38579025 | Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function |
| Q42078124 | New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins |
| Q44397753 | PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets |
| Q34453808 | PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis |
| Q26795765 | Role of ZAC1 in transient neonatal diabetes mellitus and glucose metabolism |
| Q37049098 | Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications |
| Q35962745 | Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review |
| Q43975277 | The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice |
| Q36040879 | Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs |
| Q37774288 | Trophic effects of PACAP on pancreatic islets: a mini-review. |
| Q46381956 | What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? |
Search more.